U.S. markets closed

aTyr Pharma, Inc. (LIFE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.9100+0.2700 (+7.42%)
At close: 4:00PM EDT

3.9200 +0.01 (0.26%)
After hours: 6:35PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Megaphone Top

Megaphone Top

Previous Close3.6400
Open3.6500
Bid3.6500 x 4000
Ask3.9900 x 1100
Day's Range3.5004 - 3.9900
52 Week Range2.1300 - 7.6200
Volume155,783
Avg. Volume100,651
Market Cap36.599M
Beta (5Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-3.5200
Earnings DateAug 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Atyr Pharma (LIFE) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Atyr Pharma (LIFE) Reports Q2 Loss, Misses Revenue Estimates

    Atyr Pharma (LIFE) delivered earnings and revenue surprises of 5.48% and -52.75%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs

    Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDTSAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced second quarter results and provided a corporate update. “While the advent of the global COVID-19 pandemic impacted our Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis, hindering patient enrollment during the second quarter, I am pleased that the majority of our sites are now continuing enrollment. Due to the strong scientific rationale of ATYR1923’s mechanism of action and its overlap with COVID-19 disease pathology, including inflammatory lung injury, during the second quarter we also initiated a Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications,” said Dr. Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.“Additionally, we continue to drive value and build momentum with our pipeline. The preclinical data resulting from our Neuropilin-2 (NRP2) antibody program in oncology demonstrates tumor inhibitory effects and we expect to declare an Investigational New Drug (IND) candidate later this year. We also expect to complete the first phase of our tRNA synthetase research collaboration with CSL Behring early in the fourth quarter.”Second Quarter 2020 and Subsequent Period Highlights * Progressed our ongoing Phase 1b/2a clinical trial of ATYR1923 in patients with pulmonary sarcoidosis. The majority of sites have now resumed clinical trial activities and we continue to work with each site to ensure the completion of the trial. * Initiated enrollment of a Phase 2 randomized, double blind, placebo-controlled study of ATYR1923 in COVID-19 patients with severe respiratory complications. An independent data and safety monitoring board conducted a pre-planned, blinded interim safety analysis of the initial five patients dosed, which resulted in a positive outcome recommending the trial continue unmodified. Enrollment is ongoing and we expect to report data from this study in the fourth quarter. * Published two abstracts in the American Journal of Respiratory and Critical Care Medicine that were also presented as posters at the 2020 American Thoracic Society International Conference Virtual Meeting. These findings characterize ATYR1923’s immunomodulatory properties and confirm that it selectively binds to NRP2, a unique target expressed on key immune cells in inflammatory conditions. Further, the research demonstrates that NRP2 is expressed in sarcoid granulomas, reinforcing its status as a key target in the treatment of immune-mediated diseases. * Presented preclinical data in a poster at the American Association for Cancer Research Virtual Annual Meeting II from our NRP2 antibody program demonstrating that one of these antibodies blocked VEGF-C binding to NRP2, showing tumor inhibitory effects and increased sensitivity to chemotherapy in preclinical models of triple-negative breast cancer. We expect to declare an IND candidate later this year from our NRP2 antibody program. * Provided an update on our collaboration and license agreement with Kyorin Pharmaceutical, Co., Ltd., for the development and commercialization of ATYR1923 for interstitial lung diseases in Japan (the Kyorin Agreement). Kyorin received a Clinical Trial Notification from Japan’s Pharmaceutical and Medical Devices agency which approves the initiation of a Phase 1 study to evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 (also known as KRP-R120) in Japanese healthy volunteers. * Announced an amendment to the tRNA synthetase research collaboration and option agreement with CSL Behring (the CSL Agreement) that extends the work on the first phase of the research program through September 30, 2020. As a result of the extension, CSL has provided additional funding for research and development activities.Second Quarter 2020 Financial ResultsTotal revenues were $0.2 million and $0.1 million for the three months ended June 30, 2020 and 2019, respectively. Revenues for the three months ended June 30, 2020 consisted of $0.1 million of license revenue under the Kyorin Agreement and $0.1 million of license revenue under the CSL Agreement while revenues for the three months ended June 30, 2019 consisted $0.1 million of license revenue under the CSL Agreement. Research and development expenses were $4.4 million and $3.3 million for the three months ended June 30, 2020 and 2019, respectively. The increase for research and development expenses was due primarily to ATYR1923 clinical activities.Total revenues were $8.3 million and $0.1 million for the six months ended June 30, 2020 and 2019, respectively. Revenues for the six months ended June 30, 2020 consisted of $8.0 million from license revenue under the Kyorin Agreement and $0.3 million from license revenue under the CSL Agreement while revenues for the six months ended June 30, 2019 consisted of $0.1 million from license revenue under the CSL Agreement. Research and development expenses were $8.0 million and $6.7 million for the six months ended June 30, 2020 and 2019, respectively. The increase for research and development expenses was due primarily to ATYR1923 clinical activities. General and administrative expenses were $4.7 million and $5.0 million for the six months ended June 30, 2020 and 2019, respectively. The decrease was due primarily to a reduction in professional fees.As of June 30, 2020, aTyr had $41.4 million in cash, cash equivalents and investments.Conference Call and Webcast DetailsaTyr Pharma will host a conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to discuss its financial results and provide a corporate update. Interested parties may access the call by dialing toll-free 844-358-9116 from the US, or 209-905-5951 internationally and using conference ID 5176802. Links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event.About ATYR1923aTyr is developing ATYR1923 as a potential therapeutic for patients with inflammatory lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr is currently enrolling a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis. This Phase 1b/2a study is a multi-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and pharmacokinetics profile of multiple doses of ATYR1923. In response to the COVID-19 pandemic, aTyr recently initiated a Phase 2 clinical trial with ATYR1923 in COVID-19 patients with severe respiratory complications. This Phase 2 study is a randomized, double blind, placebo-controlled study that has been designed to evaluate the safety and preliminary efficacy of a single dose of ATYR1923.About aTyraTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential therapeutic benefits and applications of ATYR1923 and our NRP2 antibody program; timelines and plans with respect to certain development activities (including the further development of ATYR9123 and our NRP2 antibody program); expected activities under our collaboration agreements and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the fact that NRP2 biology is not fully understood, uncertainty regarding the COVID-19 pandemic, including the risk of delays in enrollment in our clinical trials, risks associated with the discovery, development and regulation of our product candidates, including the risk that results from clinical trials or other studies may not support further development, the risk that we may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons, the fact that our collaboration agreements are subject to early termination, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.ATYR PHARMA INC.  Condensed Consolidated Statements of Operations  (in thousands, except share and per share data)            Three Months Ended June 30,  Six Months Ended  June 30,                          2020  2019  2020  2019                                                      (unaudited)   Revenues:                 License revenues $189  $94  $8,254  $94  Total revenues  189   94   8,254   94  Operating expenses:                 Research and development  4,361   3,314   7,977   6,659  General and administrative  2,146   2,421   4,736   4,953  Total operating expenses  6,507   5,735   12,713   11,612  Loss from operations  (6,318)  (5,641)  (4,459)  (11,518) Total other expense, net  (129)  (207)  (236)  (467) Consolidated net loss $(6,447) $(5,848) $(4,695) $(11,985) Net loss attributable to noncontrolling interest in Pangu BioPharma Limited  1   —   2   —  Net loss attributable to aTyr Pharma, Inc. $(6,446) $(5,848) $(4,693) $(11,985) Net loss per share, basic and diluted $(0.69) $(1.80) $(0.58) $(4.23) Shares used in computing net loss per share, basic and diluted  9,357,432   3,244,920   8,119,612   2,834,079  ATYR PHARMA INC.  Condensed Consolidated Balance Sheets  (in thousands)              June 30,  December 31,    2020  2019    (unaudited)      Cash, cash equivalents and available-for-sale investments $41,434  $31,144  Other receivables  831   100  Prepaid expenses and other assets  1,700   853  Property and equipment, net  1,136   1,270  Right-of-use assets  2,461   2,821  Total assets $47,562  $36,188            Accounts payable, accrued expenses and other liabilities $4,016  $3,431  Current portion of operating lease liability  807   755  Term loans, net of issuance costs and discount  4,976   8,737  Long-term operating lease liability, net of current portion  1,825   2,239  Total stockholders’ equity  35,938   21,026  Total liabilities and stockholders’ equity $47,562  $36,188                                 Contact:  Ashlee Dunston  Investor Relations, aTyr Pharma  adunston@atyrpharma.com

  • GlobeNewswire

    aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan

    Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan.SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has initiated clinical development in Japan for aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan) following the Pharmaceutical and Medical Devices Agency (PMDA) review of its Clinical Trial Notification (CTN) submission. The CTN permits the start of clinical development activities in Japan for ATYR1923. The Phase 1 study, which will be conducted by Kyorin, will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy male volunteers in Japan. “We are pleased with the advance of ATYR1923 to a Phase 1 study in Japan. Fulfilling the requirement to establish pharmacokinetic data for ATYR1923 in the Japanese patient population is an important step towards expanding the clinical development of our program in ILDs globally,” said Dr. Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Kyorin is a committed partner with a focus on advancing new treatments for respiratory conditions. We look forward to our continued collaboration as we work to improve outcomes for patients with ILDs.”Kyorin is aTyr’s partner for the development and commercialization of ATYR1923 for interstitial lung diseases (ILDs) in Japan. As per the agreement, aTyr previously received an $8 million upfront payment and is eligible to receive up to $167 million in the aggregate upon the achievement of certain development, regulatory and sales milestones, as well as tiered royalties on the net sales in Japan. Kyorin has the exclusive rights to commercialize ATYR1923 in Japan for ILDs.About ATYR1923aTyr is developing ATYR1923 as a potential therapeutic for patients with inflammatory lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr is currently enrolling a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis, a form of interstitial lung disease. This Phase 1b/2a study is a multi-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and pharmacokinetics profile of multiple doses of ATYR1923. In response to the COVID-19 pandemic, aTyr recently initiated a Phase 2 clinical trial with ATYR1923 in COVID-19 patients with severe respiratory complications. This Phase 2 study is a randomized, double blind, placebo-controlled study that has been designed to evaluate the safety and preliminary efficacy of a single dose of ATYR1923.About aTyraTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.About KyorinTrusted among patients and professionals in the medical industry, Kyorin Pharmaceutical Co., Ltd. strives to be a company that contributes to public health and is recognized as one with social significance by improving its presence in specific therapeutic areas and through global discovery of novel drugs. Kyorin Pharmaceutical Co., Ltd. uses a franchise customer strategy where its marketing efforts are focused on respiratory, otolaryngology and urology. In drug discovery, it is deploying 'selection and concentration' and promoting activities aimed at first-in-class drug discovery, such as actively searching for and introducing external drug discovery themes as well as multi-tiered program development. For more information, please visit http://www.kyorin-pharm.co.jp.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential therapeutic benefits and applications of ATYR1923; timelines and plans with respect to certain development activities (such as the scope and timelines of clinical trials), potential benefits of collaborations and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding the COVID-19 pandemic, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Contact: Ashlee Dunston Investor Relations and Corporate Communications adunston@atyrpharma.com